KASINGER JAMES R. 4

4 · CRISPR Therapeutics AG · Filed Mar 12, 2026

AI-generated summary of this filing

Updated Mar 12, 2026

CRISPR (CRSP) General Counsel James Kasinger Sells Shares

What Happened

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics (CRSP), had 5,500 derivative awards (restricted stock units) convert to common shares on March 10, 2026, and a portion of the resulting shares were sold. On March 11, 2026 he sold 2,800 shares in an open-market transaction at $52.80 per share for proceeds of $147,840. The conversion/vesting was from a March 10, 2023 RSU grant (22,000 shares total; quarterly vesting over four years).

Key Details

Transaction dates and prices:
- 2026-03-10: 5,500 shares converted from derivative/RSU (reported as an M-code exercise/conversion).
- 2026-03-11: 2,800 shares sold at $52.80 each for $147,840 (open-market sale).
Shares owned after transaction: Not specified in the excerpt of the filing provided.
Footnotes / notable items:
- The shares arose from RSUs granted 2023-03-10 with quarterly vesting (one quarter vested each year through 2027) (F4).
- The 2,800-share sale represents the number of shares required to be sold to cover tax withholding on vesting per the company’s RSU Settlement Policy; it was a mandated sale, not a discretionary trade (F2, F3).
- Some of the converted shares remain subject to a lock‑up agreement with underwriters related to the company’s convertible senior notes due 2031 (F1).
Filing timeliness: Form 4 was filed on 2026-03-12 for transactions dated March 10–11, 2026; this appears to be a timely filing under normal Form 4 deadlines.

Context

The March 10 entries reflect conversion/vesting of restricted stock units (derivative exercise/conversion). The subsequent sale on March 11 was to satisfy tax withholding obligations (a common, non-discretionary practice) rather than an opportunistic sell. This type of forced sale generally does not signal management’s market view.

Form 4

Period: 2026-03-10

General Counsel and Secretary

Transactions

Exercise/Conversion
Common Shares
[F1][F2]
2026-03-10+5,500→ 90,615 total
Sale
Common Shares
[F3]
2026-03-11$52.80/sh−2,800$147,840→ 87,815 total
Exercise/Conversion
Restricted Stock Units
[F2][F1][F4]
2026-03-10−5,500→ 5,500 total
→ Common Shares (5,500 underlying)

Footnotes (4)

[F1]These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
[F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
[F3]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
[F4]This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

Signature

/s/ Elizabeth Ryland Waldinger, attorney-in-fact|2026-03-12

1 file